AI stock analysis · Health Information Services · Last analyzed Jul 8, 2026
Compass Score
3.0/5
Call
Hold
Price
$6.78
AI Target
$7.48 +10.4%
AI Analyst Summary
Certara is a biosimulation and regulatory software platform serving the pharmaceutical industry, offering recurring software and services revenue with a modest forward P/E of 16.4x — but the bull case is undermined by near-flat revenue growth of just 0.9% YoY, ongoing losses on a trailing basis, and a deeply inconsistent earnings track record of just 1 beat in the last 4 quarters. The primary near-term risk is continued revenue stagnation in a segment that demands high growth to justify its valuation premium, compounded by weak execution against analyst expectations.
Catalysts
Acceleration in biosimulation software adoption as drug developers increasingly rely on model-informed drug development to reduce clinical trial costs — a reacceleration to mid-single-digit or higher revenue growth in Q3/Q4 would shift sentiment materially.
Potential new regulatory mandates or FDA guidance reinforcing the use of biosimulation in drug submissions could serve as a structural demand catalyst for Certara's core platform.
Any evidence of margin expansion or a return to positive EPS in upcoming quarters would validate the 16.4x forward P/E and could trigger analyst estimate upgrades.
Fundamentals
PeN/A (loss-making) · 1.0/5
No trailing P/E available — company is currently loss-making. Forward P/E of 16.4x is modest but profitability has not yet been established on a trailing basis.
PegN/A · 2.0/5
PEG ratio is unavailable due to lack of trailing earnings. Revenue growth of just 0.9% YoY suggests very limited growth momentum, warranting a below-average score despite the low forward P/E.
Analyst RatingBuy consensus (2.3) · 4.0/5
Consensus rating of 2.3 falls in the 1.5–2.5 Buy range. Breakdown of 4 Buy / 7 Hold / 0 Sell across 10 analysts reflects cautious but net-positive sentiment. Analyst count exceeds the 5-analyst threshold for a full score.
Earnings growth is not available and the company is loss-making. Revenue growth of 0.9% YoY is near-flat and well below what would be expected for a premium healthcare software company, signaling a meaningful deceleration in business momentum.
Price Target Beat1 of 4 quarters beat · 1.0/5
EPS beat rate of just 1 of 4 recent quarters is well below expectations. This persistent underdelivery relative to consensus estimates is a significant red flag for execution quality.
ManagementWeak execution signals · 2.0/5
A 1-of-4 EPS beat rate combined with near-zero revenue growth suggests management has struggled to deliver on guidance. Analyst sentiment remains cautiously constructive but is not strongly bullish, reflecting limited confidence in near-term execution.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.